biostudies-literatureToma WVCU Massey Cancer CenterNCI NIH HHSNIH-NCI Cancer CenterNIH305-315https://www.ebi.ac.uk/biostudies/studies/S-EPMC5489229biostudies-literatureUnknown117Paclitaxel, one of the most commonly used cancer chemotherapeutic drugs, effectively extends the progression-free survival of breast, lung, and ovarian cancer patients. However, paclitaxel and other chemotherapy drugs elicit peripheral nerve fiber dysfunction or degeneration that leads to peripheral neuropathy in a large proportion of cancer patients. Patients receiving chemotherapy also often experience changes in mood, including anxiety and depression. These somatic and affective disorders represent major dose-limiting side effects of chemotherapy. Consequently, the present study was designed to develop a preclinical model of paclitaxel-induced negative affective symptoms in order to identify treatment strategies and their underlying mechanisms of action. Intraperitoneal injections of paNeuropharmacologyEffects of paclitaxel on the development of neuropathy and affective behaviors in the mouse.PMC5489229R01 CA206028R01-CA206028P30 CA016059Toma WBigbee JWKyte SLDamaj MIChen ZJDel Fabbro EAlsharari SDLichtman AHBagdas DAlkhlaif YGewirtz DAfalseEffects of paclitaxel on the development of neuropathy and affective behaviors in the mouse.Paclitaxel, one of the most commonly used cancer chemotherapeutic drugs, effectively extends the progression-free survival of breast, lung, and ovarian cancer patients. However, paclitaxel and other chemotherapy drugs elicit peripheral nerve fiber dysfunction or degeneration that leads to peripheral neuropathy in a large proportion of cancer patients. Patients receiving chemotherapy also often experience changes in mood, including anxiety and depression. These somatic and affective disorders represent major dose-limiting side effects of chemotherapy. Consequently, the present study was designed to develop a preclinical model of paclitaxel-induced negative affective symptoms in order to identify treatment strategies and their underlying mechanisms of action. Intraperitoneal injections of pa2017-01-01T00:00:00Z2017 May2025-08-13T03:06:20.268Z2025-08-13T03:06:20.268ZS-EPMC54892292823780710.1016/j.neuropharm.2017.02.020